Pharmacogenetics and beyond: variability of voriconazole plasma levels in a patient with primary immunodeficiency.

about

Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014.PharmGKB summary: voriconazole pathway, pharmacokinetics.

P2860

Q38284468-AD5CB31B-7260-470A-B4D7-8F84A9947F3C Q38918175-A3FFAEAD-3D6A-484A-A55A-7C4F2EF0AFF3

P2860

Pharmacogenetics and beyond: variability of voriconazole plasma levels in a patient with primary immunodeficiency.

Item

http://www.wikidata.org/entity/Q42283754

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Pharmacogenetics and beyond: v ...... with primary immunodeficiency.

@en

Pharmacogenetics and beyond: v ...... with primary immunodeficiency.

@nl

type

Item

label

Pharmacogenetics and beyond: v ...... with primary immunodeficiency.

@en

Pharmacogenetics and beyond: v ...... with primary immunodeficiency.

@nl

prefLabel

Pharmacogenetics and beyond: v ...... with primary immunodeficiency.

@en

Pharmacogenetics and beyond: v ...... with primary immunodeficiency.

@nl

P1476

Pharmacogenetics and beyond: v ...... with primary immunodeficiency.

@en

P2093

Bruce Tapiéro

http://www.w3.org/2001/XMLSchema#string

Catherine Litalien

http://www.w3.org/2001/XMLSchema#string

Christopher Marquis

http://www.w3.org/2001/XMLSchema#string

Julie Autmizguine

http://www.w3.org/2001/XMLSchema#string

Julie Rousseau

http://www.w3.org/2001/XMLSchema#string

Maja Krajinovic

http://www.w3.org/2001/XMLSchema#string

Philippe Ovetchkine

http://www.w3.org/2001/XMLSchema#string

Yves Théorêt

http://www.w3.org/2001/XMLSchema#string

P2860

Voriconazole therapeutic drug monitoring.

Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America

In vitro hepatic metabolism explains higher clearance of voriconazole in children versus adults: role of CYP2C19 and flavin-containing monooxygenase 3

International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics.

Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.

Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodified hemopoietic allograft: a survey of the European experience, 1985-2000.

Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes.

Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers.

Antifungal therapeutic drug monitoring: established and emerging indications.

Pharmacokinetic variability of voriconazole and N-oxide voriconazole measured as therapeutic drug monitoring.

P304

1961-1965

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/PGS.12.175

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23215888

http://www.w3.org/2001/XMLSchema#string

Pharmacogenetics and beyond: variability of voriconazole plasma levels in a patient with primary immunodeficiency.

about

P2860

P2860

Pharmacogenetics and beyond: variability of voriconazole plasma levels in a patient with primary immunodeficiency.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698